doi: 10.3389/fmed.2024.1442525 Received 02 June 2024 Accepted 30 October 2024 Published 14 November 2024 Volume 11 - 2024 Edited by Thierry Thvenot, University Hospital of Besanon, France Reviewed by Qianqian Zhang, First Affiliated Hospital of Anhui Medical University, China Jonathan Soldera, University of Caxias do Sul, Brazil Juan Pablo Roblero, Clinical Hospital of the University of Chile, Chile Updates Copyright 2024 Philips
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK Dizziness may result from dehydration due to gastrointestinal side effects, hypoglycaemia when combined with other diabetes medications, or reduced caloric intake Seek urgent medical attention if dizziness occurs with chest pain, severe headache, stroke symptoms, loss of consciousness, or severe abdominal pain Management includes maintaining adequate hydration, rising slowly from sitting or lying positions, monitoring blood glucose levels, and ensuring balanced nutrition Report persistent or concerning symptoms to your GP or via the MHRA Yellow Card Scheme for ongoing medication safety monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus
Additionally, the relatively short duration of our study may not have captured long-term effects or potential changes in parameters such as stress levels
What is the most important information I should know about fluoxetine tablets
As with any supplement, individual results vary, and consistency is key
